{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=combined+therapy+treatment&page=29", "query": { "intervention": "combined therapy treatment", "page": 29 }, "page_size": 10 }, "pagination": { "page": 29, "page_size": 10, "total_count": 12517, "total_pages": 1252, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=combined+therapy+treatment&page=30&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=combined+therapy+treatment&page=28&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-15T09:32:21.176Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02574741", "title": "Combination Treatment for Augmenting Language in Children With ASD", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Autism Spectrum Disorder" ], "interventions": [ { "name": "Behavioral Therapy", "type": "BEHAVIORAL" }, { "name": "Aripiprazole", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "BEHAVIORAL", "DRUG" ], "sponsor": "University of California, Los Angeles", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "5 Years", "maximum_age": "11 Years", "sex": "ALL", "summary": "5 Years to 11 Years" }, "enrollment_count": 58, "start_date": "2012-06", "completion_date": "2019-12", "has_results": false, "last_update_posted_date": "2020-04-29", "last_synced_at": "2026-10-15T09:32:21.176Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02574741" }, { "nct_id": "NCT00029341", "title": "A Study to Demonstrate That Anti-HIV Drug Therapy Can be Stopped Without Causing Viral Resistance, and to Characterize Drug Elimination From the Body", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Treatment Interruption", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2008-07-30", "last_synced_at": "2026-10-15T09:32:21.176Z", "location_count": 7, "location_summary": "San Francisco, California • Denver, Colorado • Cincinnati, Ohio + 2 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Providence", "state": "Rhode Island" }, { "city": "Providence", "state": "Rhode Island" } ], "official_url": "https://clinicaltrials.gov/study/NCT00029341" }, { "nct_id": "NCT00846131", "title": "Y-90 Alone or With Sorafenib for Pre-Transplant Hepatocellular Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hepatocellular Carcinoma" ], "interventions": [ { "name": "Sorafenib", "type": "DRUG" }, { "name": "Yttrium-90 (Y-90)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2009-02", "completion_date": "2016-09", "has_results": false, "last_update_posted_date": "2016-09-15", "last_synced_at": "2026-10-15T09:32:21.176Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00846131" }, { "nct_id": "NCT00003753", "title": "Floxuridine, Dexamethasone, and Irinotecan After Surgery in Treating Patients With Liver Metastases From Colorectal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colorectal Cancer", "Metastatic Cancer" ], "interventions": [ { "name": "dexamethasone", "type": "DRUG" }, { "name": "floxuridine", "type": "DRUG" }, { "name": "irinotecan hydrochloride", "type": "DRUG" }, { "name": "adjuvant therapy", "type": "PROCEDURE" }, { "name": "conventional surgery", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "1998-09", "completion_date": "2004-04", "has_results": false, "last_update_posted_date": "2013-06-24", "last_synced_at": "2026-10-15T09:32:21.176Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003753" }, { "nct_id": "NCT00517439", "title": "A Study of Hepatitis C Virus (HCV) Polymerase Inhibitor Pro-Drug in Combination With PEGASYS Plus COPEGUS Compared With PEGASYS Plus COPEGUS in Patients With Chronic Hepatitis C Genotype 1 Infection.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C, Chronic" ], "interventions": [ { "name": "Copegus", "type": "DRUG" }, { "name": "Pegasys", "type": "DRUG" }, { "name": "RO4588161", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 516, "start_date": "2007-12", "completion_date": "2010-01", "has_results": false, "last_update_posted_date": "2016-11-02", "last_synced_at": "2026-10-15T09:32:21.176Z", "location_count": 30, "location_summary": "Phoenix, Arizona • La Jolla, California • Long Beach, California + 26 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00517439" }, { "nct_id": "NCT04993677", "title": "A Study of SEA-CD40 Given With Other Drugs in Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma", "Carcinoma, Non-Small- Cell Lung" ], "interventions": [ { "name": "SEA-CD40", "type": "DRUG" }, { "name": "pembrolizumab (KEYTRUDA®)", "type": "DRUG" }, { "name": "pemetrexed", "type": "DRUG" }, { "name": "carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Seagen Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 77, "start_date": "2021-10-06", "completion_date": "2024-11-25", "has_results": true, "last_update_posted_date": "2025-05-11", "last_synced_at": "2026-10-15T09:32:21.176Z", "location_count": 23, "location_summary": "Springdale, Arkansas • Los Angeles, California • San Francisco, California + 18 more", "locations": [ { "city": "Springdale", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Fort Myers", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04993677" }, { "nct_id": "NCT00315757", "title": "Study of Mapatumumab in Combination With Bortezomib (Velcade) and Bortezomib Alone in Subjects With Relapsed or Refractory Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Mapatumumab", "type": "BIOLOGICAL" }, { "name": "Bortezomib", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Human Genome Sciences Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 105, "start_date": "2006-05", "completion_date": "2010-10", "has_results": false, "last_update_posted_date": "2013-08-08", "last_synced_at": "2026-10-15T09:32:21.176Z", "location_count": 8, "location_summary": "Scottsdale, Arizona • La Jolla, California • Lecanto, Florida + 5 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Lecanto", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00315757" }, { "nct_id": "NCT04667481", "title": "Adaptive Training Exercise Programs for Improving Cardiorespiratory Fitness After Breast Cancer Treatment, The ACTIVATE Trial", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Breast Cancer", "Invasive Breast Carcinoma" ], "interventions": [ { "name": "Aerobic Exercise Intervention", "type": "OTHER" }, { "name": "Resistance Exercise Intervention", "type": "OTHER" }, { "name": "Exercise Intervention: Digital copies and outline of sessions", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "FEMALE", "summary": "18 Years to 75 Years · Female only" }, "enrollment_count": 27, "start_date": "2022-01-05", "completion_date": "2022-11-10", "has_results": true, "last_update_posted_date": "2024-02-12", "last_synced_at": "2026-10-15T09:32:21.176Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT04667481" }, { "nct_id": "NCT04008030", "title": "A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Colorectal Cancer" ], "interventions": [ { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" }, { "name": "Nivolumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 839, "start_date": "2019-08-05", "completion_date": "2027-03-23", "has_results": true, "last_update_posted_date": "2026-08-20", "last_synced_at": "2026-10-15T09:32:21.176Z", "location_count": 9, "location_summary": "Los Angeles, California • Sacramento, California • Denver, Colorado + 6 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Arlington Heights", "state": "Illinois" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04008030" }, { "nct_id": "NCT00002369", "title": "A Comparison of Epivir Plus Crixivan Combined With Zerit or Retrovir in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Indinavir sulfate", "type": "DRUG" }, { "name": "Lamivudine", "type": "DRUG" }, { "name": "Stavudine", "type": "DRUG" }, { "name": "Zidovudine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 200, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2007-10-02", "last_synced_at": "2026-10-15T09:32:21.176Z", "location_count": 9, "location_summary": "Birmingham, Alabama • Fort Lauderdale, Florida • Tampa, Florida + 6 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Fort Lauderdale", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "New Orleans", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002369" } ] }